CVE-2026-50034: BLE Glucose Data Eavesdropping Vulnerability – Passive Interception Risk

Technical summary

The vulnerability stems from insufficient cryptographic protection of BLE traffic (CWE-319: Cleartext Transmission of Sensitive Information). An unauthenticated, adjacent-network attacker can passively capture wireless frames containing glucose readings without triggering any authentication or encryption mechanisms. The CVSS 3.1 score of 6.5 reflects a high confidentiality impact with no integrity or availability compromise. The attack requires physical proximity (AV:A) and no complexity (AC:L), user interaction (UI:N), or privileges (PR:N), making passive interception trivial once an attacker is within BLE range (typically 10–100 meters depending on device power settings).

Business impact

For organizations deploying connected glucose monitors or similar BLE-enabled health devices, this vulnerability poses a direct patient privacy risk. Exposed glucose readings can infer medical conditions, treatment patterns, and health status—information regulable under HIPAA, GDPR, and regional health privacy frameworks. Depending on device deployment (corporate wellness programs, health systems, or home use), breach notification obligations and reputational damage may follow. The passive nature limits immediate exploitation risk but does not eliminate it in environments with persistent attacker presence (e.g., workplaces, hospitals, shared living spaces).

Affected systems

No specific vendor or product list was provided in the CVE record. Organizations must consult vendor advisories and device documentation to determine which BLE health devices are affected. Any glucose monitoring device or similar health sensor relying on unencrypted or weakly protected BLE communication may be vulnerable. Prioritize inventory of connected medical devices and cross-reference against vendor security notices.

Exploitability

Passive interception requires only a BLE-capable radio and proximity to the target device—tools and knowledge are widely available. However, exploitation does not grant attackers control over the device or data modification; they can only read transmitted values. The absence of active exploitation (no packet injection, no device compromise) lowers the barrier to passive eavesdropping but also means the attack is less intrusive than active compromise. The vulnerability is not listed on the CISA Known Exploited Vulnerabilities catalog, suggesting limited real-world weaponization to date, though this does not indicate the flaw is difficult to exploit in practice.

Remediation

Affected device manufacturers should release firmware or hardware revisions that implement robust encryption (e.g., AES-CCM with authenticated encryption) for BLE glucose data transmission. Devices should enforce encryption negotiation and reject unencrypted or weakly authenticated connections. Organizations deploying vulnerable devices should check vendor advisories for patch availability and apply updates promptly. Until patches are available, compensating controls such as radio frequency shielding, network segmentation, or device proximity monitoring may reduce exposure in high-risk environments.

Patch guidance

Consult the device vendor's security advisory for specific patch version numbers and deployment procedures. Patches, if available, are likely to be delivered as firmware updates via the device's companion mobile app or web portal. Test patches in a non-production environment first, especially if the device is integrated into clinical workflows. Verify patch application by confirming BLE encryption negotiation in device logs or via wireless packet analysis. Until patched, consider restricting use of vulnerable devices in public or shared spaces.

Detection guidance

Network defenders can detect BLE eavesdropping indirectly by monitoring for unexpected BLE device discovery, unusual wireless traffic patterns near medical device clusters, or anomalous connection attempts from unrecognized MAC addresses. Wireless intrusion detection systems (WIDS) or BLE-specific scanning tools can identify unencrypted health device broadcasts. Direct detection of passive eavesdropping is difficult, but anomalous device behavior (e.g., rapid repeated readings, unexpected data access) may indicate a nearby attacker attempting data exfiltration. Health device vendors should instrument logging to track BLE connection quality and authentication failures.

Why prioritize this

Although the CVSS score is moderate (6.5), the medical sensitivity of glucose data and the ease of passive interception warrant expedited patching. Health devices face regulatory and liability pressures; breaches can trigger compliance violations and patient notifications. The lack of active exploitation pathways and absence from the KEV catalog suggest lower immediate threat, but organizations with glucose monitoring deployments should still prioritize remediation to avoid privacy incidents.

Risk score, explained

The CVSS 3.1 score of 6.5 (MEDIUM) reflects high confidentiality impact (C:H) with no integrity or availability effects (I:N, A:N). The attack vector is adjacent (AV:A), meaning attacker proximity is required, and low complexity (AC:L) indicates straightforward passive eavesdropping. No special privileges (PR:N) or user interaction (UI:N) are needed. The unchanged scope (S:U) means the flaw does not cross privilege boundaries. While the numerical score is moderate, the medical nature of exposed data and regulatory context elevate practical risk beyond the score alone.

Frequently asked questions